🇺🇸 Peginterferon alfa 2 in United States

16 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 16

Most-reported reactions

1. Anaemia — 3 reports (18.75%)
2. Anal Pruritus — 2 reports (12.5%)
3. Haemoglobin Decreased — 2 reports (12.5%)
4. Rash — 2 reports (12.5%)
5. Rash Generalised — 2 reports (12.5%)
6. Abdominal Pain Upper — 1 report (6.25%)
7. Alanine Aminotransferase Increased — 1 report (6.25%)
8. Alopecia — 1 report (6.25%)
9. Anal Inflammation — 1 report (6.25%)
10. Anti-Erythropoietin Antibody Positive — 1 report (6.25%)

Source database →

Frequently asked questions

Is Peginterferon alfa 2 approved in United States?

Peginterferon alfa 2 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Peginterferon alfa 2 in United States?

Dr. Conrado Fernandez is the originator. The local marketing authorisation holder may differ — check the official source linked above.